Education
About Us
Working with TipRanks
Follow Us
Allurion Technologies, Inc. (ALUR)
:ALUR
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.57Last Year’s EPS
2.75Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: -21.86%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with key achievements in procedure volume growth, successful combination therapy results, and operational restructuring leading to reduced expenses. However, these were countered by significant revenue and gross profit margin declines, as well as a notable loss from operations.Company Guidance
In the recent earnings call, Allurion Technologies provided several key metrics and insights regarding its performance and strategic plans. For the fourth quarter of 2024, the company reported revenue of $5.6 million, contributing to a total annual revenue of $32.1 million. Despite a 39% reduction in operating expenses compared to the previous year, procedure volumes increased by 4%, exceeding prior guidance. Allurion is focusing on a new commercial strategy emphasizing a business-to-business-to-consumer (B2B2C) approach and aims to expand its sales team in 2025. The company expects operating expenses to decrease by approximately 50% in 2025, targeting revenues of around $30 million. Additionally, Allurion plans to achieve profitability for its ex-US business by the end of 2025, with efforts underway to secure FDA approval for its Allurion Balloon. The financial restructuring and new commercial strategies are anticipated to drive growth and efficiency as the company progresses towards its long-term goals.Procedure Volume Growth
In 2024, procedure volumes grew by 4%, exceeding previous guidance. This growth is attributed to patients entering the funnel after discontinuing GLP-1 medications.
Operating Expense Reduction
Operating expenses decreased by 39% in Q4 2024 compared to the previous year, showing the positive impact of restructuring and reorganization initiatives.
Successful Combination Therapy
Studies showed promising results for the Allurion Balloon combined with low dose GLP-1s, leading to significant weight loss and muscle mass preservation.
Commercial Plan Progress
Significant progress in implementing a new commercial plan focused on key geographies and a B2B2C sales model, with procedure volumes in pilot accounts set to increase by over 30% in Q1 2025 compared to Q4 2024.
Resumption of Sales in France
Sales in France have resumed after regulatory clearance, with plans to reengage with clinics to serve patients.
---
ALUR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALUR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $3.11 | $3.12 | +0.32% |
| Nov 13, 2024 | $17.76 | $13.08 | -26.35% |
| Aug 13, 2024 | $19.88 | $19.46 | -2.11% |
| May 14, 2024 | $48.50 | $52.75 | +8.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Allurion Technologies, Inc. (ALUR) report earnings?
Allurion Technologies, Inc. (ALUR) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Allurion Technologies, Inc. (ALUR) earnings time?
Allurion Technologies, Inc. (ALUR) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALUR EPS forecast?
ALUR EPS forecast for the fiscal quarter 2025 (Q1) is -1.57.
---